Clinical trials: Primary Insomnia
Sleep Initiation and Maintenance Disorders
Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia
The primary objective is to evaluate the hypnotic efficacy of zolpidem-MR (modified release) 12.5 mg and zolpidem 10 mg marketed product in comparison with placebo in patients with primary insomnia and sleep maintenance…
- Trial name
- NCT00630175
- Testing
- zolpidem-MR (modified release), zolpidem (SL800750)
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 113 people
- Sponsor
- Sanofi
Sleep Initiation and Maintenance Disorders
A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia
A study to investigate the effects of GW679769 on sleep and cognition. Potential subjects participate in a clinical screening visit and a two-night PSG recording session in the sleep laboratory.
- Trial name
- NCT00650871
- Testing
- GW679769
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Primary Insomnia
A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia
- Trial name
- NCT00209937
- Testing
- Gaboxadol
- Volunteers
- 675 people
- Sponsor
- H. Lundbeck A/S
Insomnia
Evaluation of a Food Supplement on Sleep Quality
The purpose of this study is to evaluate the efficacy on sleep quality of a food supplement.
- Trial name
- Cyclamax (NCT00484497)
- Testing
- cyclamax
- Where
- France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Persee Medica
Insomnia
A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)
The purpose of this trial is to investigate the efficacy, safety and tolerability of esmirtazapine (Org 50081) compared to placebo in patients with chronic primary insomnia.
- Trial name
- NCT00506389
- Testing
- Esmirtazapine
- Volunteers
- 419 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Insomnia
Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients
This is a phase II study. It is conducted using a randomized, double-blind, 3-arm placebo controlled, parallel group design. Eligible patients will be randomized in a 1:1:1 ratio to receive Neu-P11 20 mg, Neu-P11 50 mg or placebo…
- Trial name
- NCT01489969
- Testing
- Neu-P11
- Where
- 9 sites in United States
- Volunteers
- 137 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Primary Insomnia
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)
The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.
- Trial name
- NCT00094666
- Testing
- MK0928, gaboxadol / Duration of Treatment - 6 weeks
- Volunteers
- 465 people
- Sponsor
- H. Lundbeck A/S
Insomnia
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)
The purpose of this trial is to study the safety and effectiveness of MK0928 for adults with insomnia.
- Trial name
- NCT00095069
- Testing
- MK0928, gaboxadol / Duration of Treatment - 1 year
- Volunteers
- 600 people
- Sponsor
- H. Lundbeck A/S
Primary Insomnia
Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia
This study is designed to compare 2 doses of APD125 (20 mg and 40 mg) with placebo in otherwise healthy adults with primary insomnia primarily with complaints of maintaining sleep.
- Trial name
- NCT00664664
- Testing
- APD125
- Where
- United States
- Volunteers
- 744 people
- Sponsor
- Arena Pharmaceuticals
Bladder Function
Pilot Trial in Sleep Laboratory Setting to Compare the Physiology of Night Time Bladder Function in Subjects With Overactive Bladder (OAB) Versus Subjects That Have Insomnia and Healthy Normal Subjects
This is an observational, physiology pilot study of subjects with overactive bladder, insomnia and normal subjects. No study drug will be given. All subjects will complete a one week sleep diary and a 3-day bladder diary.
- Trial name
- Nocturia Plt 1 (NCT01029015)
- Testing
- cystometry, polysomnography
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Sleep Initiation and Maintenance Disorders
Efficacy and Safety of KI1001 in ≥ 55 Years Old Insomnia Patients
KI1001(Circadin®, Prolonged release tablet which contains melatonin) has showed its efficacy to improve sleep quality in over 55 years old primary insomnia patients.
- Trial name
- NCT01450228
- Testing
- KI1001
- Where
- 10 sites in South Korea
- Volunteers
- 170 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Primary Insomnia
Effects of One Evening Dose of 3 mg Eszopiclone on Next Day Driving Ability
To assess next day driving ability and psychomotor/memory function following a single night time dose of eszopiclone in insomnia patients.
- Trial name
- NCT00368056
- Testing
- Eszopiclone
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Sumitomo Pharma America, Inc.
Tension Headaches, Stress
Temple Massager System Study in Women Ages 35-65
The goal of this observational study is to learn how the Temple Massager System affects stress, emotional wellbeing, sleep, and quality of life in women aged 35 to 65.
- Conditions
- Tension Headaches, Stress, Sleep Quality, Quality of Life
- Trial name
- NCT07639658
- Testing
- Temple Massager System
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Meisch Temple Massager, Inc.
Chronic Primary Insomnia
Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
A 2-night polysomnography / 5-way cross-over study to evaluate the effect, safety and tolerability of oral administration of almorexant (ACT 078573) in elderly subjects with primary insomnia.
- Trial name
- NCT00606593
- Where
- 21 sites in United States
- Volunteers
- 112 people
- Sponsor
- Midnight Pharma, LLC
Sleep Initiation and Maintenance Disorders, Mental Disorders
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
This trial is a 26-week, open label extension trial to investigate safety and explore efficacy of esmertazapine in participants with insomnia who completed protocol 21106/P05701/MK-8265-002 (NCT00631657).
- Conditions
- Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias, Sleep Disorders
- Trial name
- NCT00750919
- Testing
- esmirtazapine
- Volunteers
- 184 people
- Sponsor
- Merck Sharp & Dohme LLC
Sleep Initiation and Maintenance Disorders, Insomnia
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia
This study is designed to find the optimal (best) doses of GW679769 that promote sleep onset and maintain sleep during two consecutive nights of dosing without significant next-day thinking impairment and drowsiness in subjects…
- Trial name
- NCT00280436
- Testing
- GW679769
- Where
- 26 sites in United States
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Primary Insomnia
Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
The objective of this study is to determine the efficacy of a portable biofeedback device on improving sleep latency and other sleep variables such as nocturnal awake time and daytime functioning in persons with primary insomnia.
- Trial name
- NCT00415714
- Testing
- Portable Biofeedback
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Helicor
Primary Insomnia, Secondary Insomnia
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
- Trial name
- SLUMBER (NCT00784875)
- Testing
- LY2624803, zolpidem
- Where
- 49 sites in United States
- Volunteers
- 643 people
- Sponsor
- Eli Lilly and Company
Primary Insomnia
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
A cross-over, polysomnography study to test the safety, tolerability and effectiveness of different doses of suvorexant (MK-4305) in the treatment of patients with primary insomnia.
- Trial name
- NCT00792298
- Testing
- Suvorexant
- Volunteers
- 254 people
- Sponsor
- Merck Sharp & Dohme LLC
Insomnia, Sleep Initiation and Maintenance Disorders
Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)
This study was conducted to investigate the efficacy of treatment with Org 50081 (Esmirtazapine) compared to placebo in elderly participants with chronic primary insomnia.
- Conditions
- Insomnia, Sleep Initiation and Maintenance Disorders, Mental Disorders, Dyssomnias
- Trial name
- NCT00561821
- Testing
- Esmirtazapine
- Volunteers
- 538 people
- Sponsor
- Merck Sharp & Dohme LLC